Letarte N - Search Results

1

Bevacizumab and central nervous system (CNS) hemorrhage.

Letarte N, Bressler LR, Villano JL. Letarte N, et al. Cancer Chemother Pharmacol. 2013 Jun;71(6):1561-5. doi: 10.1007/s00280-013-2155-4. Epub 2013 Apr 6. Cancer Chemother Pharmacol. 2013. PMID: 23564377 Review.

2

Hematologic adverse events associated with temozolomide.

Villano JL, Letarte N, Yu JM, Abdur S, Bressler LR. Villano JL, et al. Among authors: letarte n. Cancer Chemother Pharmacol. 2012 Jan;69(1):107-13. doi: 10.1007/s00280-011-1679-8. Epub 2011 May 26. Cancer Chemother Pharmacol. 2012. PMID: 21614470

3

Going past the data for temozolomide.

Villano JL, Letarte N, Bressler LR. Villano JL, et al. Among authors: letarte n. Cancer Chemother Pharmacol. 2012 Apr;69(4):1113-5. doi: 10.1007/s00280-011-1796-4. Epub 2011 Dec 7. Cancer Chemother Pharmacol. 2012. PMID: 22147076 Clinical Trial.

4

Analyzing temozolomide medication errors: potentially fatal.

Letarte N, Gabay MP, Bressler LR, Long KE, Stachnik JM, Villano JL. Letarte N, et al. J Neurooncol. 2014 Oct;120(1):111-5. doi: 10.1007/s11060-014-1523-1. Epub 2014 Jul 16. J Neurooncol. 2014. PMID: 25026995 Free PMC article.

5

Safe administration of docetaxel after weekly paclitaxel-induced acute pancreatitis.

Adam JP, Gauthier P, Letarte N. Adam JP, et al. Among authors: letarte n. J Oncol Pharm Pract. 2017 Oct;23(7):540-544. doi: 10.1177/1078155216660184. Epub 2016 Jul 27. J Oncol Pharm Pract. 2017. PMID: 27466225

6

Single agent trabectedin in heavily pretreated patients with recurrent ovarian cancer.

Adam JP, Boumedien F, Letarte N, Provencher D. Adam JP, et al. Among authors: letarte n. Gynecol Oncol. 2017 Oct;147(1):47-53. doi: 10.1016/j.ygyno.2017.07.123. Epub 2017 Jul 24. Gynecol Oncol. 2017. PMID: 28751117

7

Effect of mannitol on acute kidney injury induced by cisplatin.

Bégin AM, Monfette ML, Boudrias-Dalle É, Lavallée E, Samouelian V, Soulières D, Chagnon M, Fournier MA, Letarte N, Adam JP. Bégin AM, et al. Among authors: letarte n. Support Care Cancer. 2021 Apr;29(4):2083-2091. doi: 10.1007/s00520-020-05703-7. Epub 2020 Aug 30. Support Care Cancer. 2021. PMID: 32862356

8

Management of adverse events related to first-generation tyrosine receptor kinase inhibitors in adults: a narrative review.

Martineau C, Turcotte MK, Otis N, Provost F, Themens L, Guay MP, Letarte N, Adam JP. Martineau C, et al. Among authors: letarte n. Support Care Cancer. 2022 Dec;30(12):10471-10482. doi: 10.1007/s00520-022-07401-y. Epub 2022 Nov 3. Support Care Cancer. 2022. PMID: 36326907 Review.

9

Use of Intermediate Endpoints in the Economic Evaluation of New Treatments for Advanced Cancer and Methods Adopted When Suitable Overall Survival Data are Not Available.

Beauchemin C, Lapierre MÈ, Letarte N, Yelle L, Lachaine J. Beauchemin C, et al. Among authors: letarte n. Pharmacoeconomics. 2016 Sep;34(9):889-900. doi: 10.1007/s40273-016-0401-4. Pharmacoeconomics. 2016. PMID: 27002517 Review.

10

Managing treatment-related adverse events associated with Alk inhibitors.

Rothenstein JM, Letarte N. Rothenstein JM, et al. Among authors: letarte n. Curr Oncol. 2014 Feb;21(1):19-26. doi: 10.3747/co.21.1740. Curr Oncol. 2014. PMID: 24523601 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

22 results

Search Page

Filters